MONOCYTE/HER2 VACCINE IN BREAST AND OVARIAN CANCER PATIENTS

用于乳腺癌和卵巢癌患者的单核细胞/HER2 疫苗

• 批准号: 6309808
• 负责人: JONATHAN R SPORN
• 金额: $ 1.91万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6309808
• 关键词: breast neoplasms; cell line; cell mediated cytotoxicity; cell transplantation; cellular immunity; clinical research; clinical trials; female; gene expression; human subject; human therapy evaluation; humoral immunity; monocyte; neoplasm /cancer genetics; neoplasm /cancer vaccine; ovary neoplasms; serology /serodiagnosis

We will study elements of the cellular and humoral immune responses in HLA-A2+ patients with breast and ovarian cancer whose tumors are HER2 positive. Patients will receive intradermal vaccination with autologous monocytes which have been made to express HER2-derived peptide by in vitro incubation with the peptide. Following vaccination they will have sampling of peripheral blood, vaccination site, saline control vaccination site, and metastatic tumor site (if accessible). Cell-mediated anti-tumor activity induced by vaccination will be studied as cells isolated from these sites are assayed in vitro for ability to lyse HER2 positive cell lines in the absence (specific cytotoxicity) or presence (antibody-dependent cytotoxicity) of in vitro anti-HER2 antibody. Humoral antitumor response before and after vaccination will be studied by assaying serum for the amount of circulating endogenous anti-HER2 antibody.

我们将研究HLA-A2+乳腺癌和卵巢癌患者的细胞和体液免疫反应的元素，这些患者的肿瘤是HER 2阳性的。 患者将接受自体单核细胞的皮内接种，所述自体单核细胞已通过与肽体外孵育而表达HER 2衍生肽。 接种疫苗后，将对受试者的外周血、接种部位、生理盐水对照接种部位和转移性肿瘤部位（如可触及）进行采样。 将研究疫苗接种诱导的细胞介导的抗肿瘤活性，因为在不存在（特异性细胞毒性）或存在（抗体依赖性细胞毒性）体外抗HER 2抗体的情况下，体外测定了从这些部位分离的细胞裂解HER 2阳性细胞系的能力。 通过测定血清中循环内源性抗HER 2抗体的量，研究接种前后的体液抗肿瘤应答。